全球切片检查市场

预计到 2030 年全球切片检查市场规模将达到 509 亿美元

全球切片检查市场规模预计在2024年为290亿美元，到2030年将达到509亿美元，2024年至2030年的复合年增长率为9.8%。本报告分析的细分市场之一——仪器——预计复合年增长率为8.6%，到分析期结束时规模将达到140亿美元。套件和耗材细分市场在分析期间的复合年增长率预计为8.4%。

美国市场预计将达到 79 亿美元，中国市场复合年增长率将达到 13.2%

美国癌症切片检查市场规模预计在2024年达到79亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到102亿美元，在2024-2030年的分析期间内，复合年增长率为13.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为7.2%和8.5%。在欧洲，预计德国市场的复合年增长率为7.7%。

全球切片检查市场—主要趋势和驱动因素摘要

为什么癌症切片检查对于准确诊断和个人化治疗至关重要？

癌症切片检查是现代肿瘤学中的关键步骤，是诊断癌症、确定肿瘤类型、分期和分级以及指导个人化治疗方案的可靠方法。切片检查包括从可疑肿块中采集组织或细胞，然后进行显微镜检查以检测恶性程度并评估特定的分子标记。这个诊断过程不仅可以确认癌症的存在，还可以提供有关肿瘤生物学行为和基因特征的重要资讯。随着癌症治疗日益转向标靶治疗和免疫治疗，准确的切片检查数据变得更加重要。医生依靠切片检查结果根据个别肿瘤特征选择最有效的治疗通讯协定，并确保治疗更合适且更成功。如果没有切片检查，治疗决策通常仅基于影像学检查和症状，而这些结果可能不确定或具有误导性。此外，切片检查常用于监测治疗反应和检测癌症復发，使其成为长期患者管理的基石。病理学、影像引导技术和分子检测的进步显着提高了切片检查的准确性和安全性。由于人口老化、生活方式改变和环境暴露，全球癌症发生率上升，透过切片检查进行早期准确诊断的需求日益迫切，这也强化了切片检查在癌症治疗过程中不可替代的作用。

技术创新如何改变切片检查技术和诊断准确性？

一系列技术进步正在彻底改变切片检查领域，这些进步提高了准确性、最大限度地减少了侵入性并实现了即时诊断。其中最重要的发展之一是影像导引切片检查技术的兴起，例如超音波切片检查、CT切片检查和 MRI 导引切片检查。这些方法确保收集到最具代表性的组织样本，从而降低了操作风险并提高了诊断产量比率。另一项重大创新是液态切片，它可以分析血液和其他切片检查中的生物标记物，例如循环肿瘤 DNA (ctDNA)、循环性肿瘤细胞(CTC) 和外泌体。这种非侵入性方法无需重复取样即可实现早期检测、动态监测治疗反应和识别抗药性突变。次世代定序(NGS) 和其他分子分析工具也在改变活检样本的分析方式，可以对肿瘤进行全面的基因组图谱绘製并发现可为精准治疗提供资讯的可操作突变。机器人和人工智慧辅助切片检查设备也开始涌现，它们提高了标靶性，并减少了操作人员的差异性。此外，数位病理学正在简化切片检查审查流程，促进更快的诊断、远端会诊以及跨癌症中心的数据整合。这些创新共同推动着从传统诊断方法转向更个人化、预测性和预防性的癌症治疗模式的转变。

影响全球切片检查需求的区域和流行病学因素有哪些？

癌症切片检查的需求受到当地医疗保健能力、癌症发病率模式和旨在早期发现的公共卫生倡议等多种因素的影响。在北美和欧洲，先进的医疗保健基础设施、广泛的癌症筛检计画和较高的意识层级促使切片检查广泛应用于各种癌症类型，包括乳癌、肺癌、大肠癌和摄护腺癌。这些地区对早期发现的重视，加上优惠的保险覆盖和报销机制，导致切片检查和先进的切片检查技术广泛应用。在亚太地区，人口老化、吸烟率上升和生活方式改变导致的癌症发病率上升正在推动切片检查服务的扩展。中国、印度和日本等国家正大力投资诊断基础设施，扩大病理实验室、影像中心和肿瘤服务的可近性。促进早期癌症检测和行动诊断设备发展的公共卫生宣传活动正在促进农村和服务不足地区的广泛采用。在拉丁美洲和非洲，获得专科医疗保健的机会有限仍然是一个挑战，但人们正在努力透过伙伴关係、捐助者资助的倡议和政府支持的筛检计画来提高癌症诊断能力。这些地区的城市中心对先进诊断方法的需求日益增长，包括液态切片和分子分析。在全球范围内，多学科癌症治疗的兴起以及切片检查与数位医疗记录的整合正在简化诊断途径并鼓励早期疗育干预。癌症发生率的地区差异，例如非洲和亚洲部分地区的子宫颈癌发生率高以及东南亚的肝癌热点，也在影响切片检查实践和特定情况通讯协定的发展。这些趋势表明，随着切片检查系统认识到活检在改善癌症预后方面的核心作用，全球切片检查利用率将激增。

推动全球切片检查市场扩张的关键因素有哪些？

切片检查市场的成长受到多种因素的驱动，包括技术进步、流行病学趋势、医疗保健政策和精准诊断的临床需求。最重要的驱动因素之一是全球癌症发生率的上升，这推动了对准确及时的诊断工具的需求，以确认恶性肿瘤并开始治疗。由于癌症仍然是全球主要的死亡原因之一，因此无论在已开发国家开发中国家，透过可靠的切片检查技术进行早期发现的紧迫性都在增加。细针抽吸、粗针穿刺切片和液态切片等微创和非侵入性切片检查技术的选择不断扩大，正在扩大患者获得活检的机会并降低与手术相关的风险。基因组定序、生物标记发现和即时影像方面的技术进步使切片检查不仅能够提供组织学数据，还能提供可指南标靶治疗和个人化治疗计划的深层分子见解。对伴随诊断和标靶药物监管核准的日益重视与透过切片检查进行准确的肿瘤分析的需求密切相关。在医疗支出不断增长和基础设施建设的支持下，医疗系统正越来越多地将切片检查服务纳入其筛检计画和癌症治疗方案。此外，患者对微创、快速、精准诊断的需求，正推动医疗保健提供者采用先进的切片检查技术。临床研究和肿瘤临床试验也推动了切片检查需求的成长，因为越来越多的研究需要采集组织样本进行合格筛检和疗效切片检查。总而言之，这些市场驱动因素凸显了切片检查市场的强劲扩张及其在现代数据主导、以患者为中心的癌症治疗中的关键作用。

部分

产品类型（仪器、套件和耗材、软体和生物资讯学、针头设备、真空辅助设备、导引系统）、程序（组织切片检查、液态切片）、癌症类型（乳癌、肺癌、结直肠癌、前列腺癌、子宫颈癌、其他癌症类型）、最终用户（医院最终用户、诊断实验室最终用户、门诊手术中心最终用户）

受访公司范例

• Agilent Technologies Inc.
• ANGLE plc
• Becton, Dickinson and Company
• Biocept Inc.
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Guardant Health Inc.
• Hologic Inc.
• Illumina Inc.
• Invitae Corporation
• Johnson & Johnson（Veridex）
• Leica Biosystems
• Menarini Silicon Biosystems
• Myriad Genetics Inc.
• Qiagen NV
• Thermo Fisher Scientific Inc.
• Veracyte Inc.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循查询 LLM 或特定产业SLM 的典型规范，而是建立了一个来自世界各地专家的精选内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Cancer Biopsies Market to Reach US$50.9 Billion by 2030

The global market for Cancer Biopsies estimated at US$29.0 Billion in the year 2024, is expected to reach US$50.9 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$14.0 Billion by the end of the analysis period. Growth in the Kits & Consumables segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.9 Billion While China is Forecast to Grow at 13.2% CAGR

The Cancer Biopsies market in the U.S. is estimated at US$7.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Cancer Biopsies Market - Key Trends & Drivers Summarized

Why Are Cancer Biopsies Indispensable to Accurate Diagnosis and Personalized Treatment?

Cancer biopsies are critical procedures in modern oncology, serving as the definitive method for diagnosing cancer, determining tumor type, stage, and grade, and guiding personalized treatment plans. A biopsy involves the extraction of tissue or cells from a suspicious mass, followed by microscopic examination to detect malignancy and assess specific molecular markers. This diagnostic process not only confirms the presence of cancer but also provides essential insights into the tumor’s biological behavior and genetic profile. As cancer treatment increasingly shifts toward targeted therapies and immunotherapies, precise biopsy data is becoming even more vital. Physicians rely on biopsy results to select the most effective treatment protocols based on an individual’s tumor characteristics, ensuring that therapy is both appropriate and potentially more successful. Without a biopsy, treatment decisions would often be based on imaging and symptoms alone, which can be inconclusive or misleading. Moreover, biopsies are frequently used to monitor treatment response and detect cancer recurrence, making them a cornerstone of long-term patient management. Advances in pathology, imaging-guided techniques, and molecular testing have significantly improved the accuracy and safety of biopsy procedures. As cancer incidence rises globally, driven by aging populations, lifestyle changes, and environmental exposures, the need for early and accurate diagnosis through biopsies is growing more urgent, reinforcing their role as an irreplaceable element in the continuum of cancer care.

How Are Technological Innovations Transforming Biopsy Techniques and Diagnostic Precision?

The field of cancer biopsies is being revolutionized by a wave of technological advancements that are enhancing precision, minimizing invasiveness, and enabling real-time diagnostics. One of the most significant developments is the rise of image-guided biopsy techniques, such as ultrasound-guided, CT-guided, and MRI-guided biopsies, which allow clinicians to target tumors with exceptional accuracy, even in anatomically complex or deep-seated locations. These methods reduce procedural risks and increase diagnostic yield by ensuring that the most representative tissue is sampled. Another major innovation is the growth of liquid biopsies, which involve analyzing biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes in blood or other body fluids. This non-invasive approach enables earlier detection, dynamic monitoring of treatment response, and identification of resistance mutations, all without the need for repeated tissue sampling. Next-generation sequencing (NGS) and other molecular profiling tools are also transforming how biopsy samples are analyzed, allowing for comprehensive genomic mapping of tumors and uncovering actionable mutations that can inform precision therapies. Robotic and AI-assisted biopsy devices are beginning to emerge, offering improved targeting and reduced variability between operators. Additionally, digital pathology is streamlining the review of biopsy slides, facilitating faster diagnoses, remote consultations, and data integration across cancer centers. Together, these innovations are driving a shift from conventional diagnostic approaches toward a more personalized, predictive, and preventive model of cancer care, where biopsies not only detect disease but also guide its management with increasing sophistication.

What Regional and Epidemiological Factors Are Shaping the Global Demand for Cancer Biopsies?

The demand for cancer biopsies is influenced by a combination of regional healthcare capacities, cancer incidence patterns, and public health initiatives aimed at early detection. In North America and Europe, advanced healthcare infrastructure, widespread cancer screening programs, and high awareness levels contribute to a high volume of biopsy procedures across diverse cancer types such as breast, lung, colorectal, and prostate cancers. The emphasis on early detection in these regions, coupled with insurance coverage and reimbursement mechanisms, supports widespread use of both traditional and advanced biopsy methods. In Asia-Pacific, rising cancer incidence due to aging populations, increased smoking rates, and lifestyle transitions is driving the expansion of biopsy services. Countries like China, India, and Japan are investing heavily in diagnostic infrastructure, expanding access to pathology labs, imaging centers, and oncology services. Public health campaigns promoting early cancer detection and the development of mobile diagnostic units are improving reach in rural and underserved areas. In Latin America and Africa, limited access to specialized healthcare remains a challenge, but efforts are underway to increase cancer diagnostic capabilities through partnerships, donor-funded initiatives, and government-supported screening programs. Urban centers in these regions are seeing growing demand for advanced diagnostic modalities, including liquid biopsies and molecular profiling. Globally, the rise of multidisciplinary cancer care and the integration of biopsies into digital health records are streamlining diagnostic pathways and encouraging early intervention. Regional variations in cancer prevalence, such as higher cervical cancer rates in parts of Africa and Asia or liver cancer hotspots in Southeast Asia, are also shaping biopsy practices and the development of context-specific protocols. These trends point to a global surge in biopsy utilization, as health systems recognize their central role in improving cancer outcomes.

What Are the Key Factors Driving the Global Expansion of the Cancer Biopsies Market?

The growth in the cancer biopsies market is driven by a constellation of factors that span technological evolution, epidemiological trends, healthcare policy, and clinical demand for precision diagnostics. One of the most significant drivers is the global rise in cancer incidence, which is increasing the need for accurate and timely diagnostic tools to confirm malignancy and initiate treatment. With cancer being a leading cause of mortality worldwide, the urgency for early detection through reliable biopsy techniques is intensifying across both developed and developing nations. The expanding availability of minimally invasive and non-invasive biopsy options, including fine-needle aspiration, core needle biopsies, and liquid biopsies, is broadening patient access and reducing procedure-related risks. Technological progress in genomic sequencing, biomarker discovery, and real-time imaging is allowing biopsies to provide not just histological data but also deep molecular insights that guide targeted therapies and personalized treatment plans. The growing emphasis on companion diagnostics and regulatory approvals for targeted drugs is tightly linked to the need for precise tumor profiling via biopsies. Health systems are increasingly integrating biopsy services into screening programs and cancer care pathways, supported by rising healthcare expenditure and infrastructure development. Additionally, patient demand for less invasive, faster, and more accurate diagnostic experiences is prompting providers to adopt advanced biopsy techniques. Clinical research and oncology trials are also driving biopsy demand as more studies require tissue sampling for eligibility screening and therapeutic monitoring. Together, these drivers reflect a robust and expanding market for cancer biopsies, underscoring their foundational role in modern, data-driven, and patient-centric cancer care.

SCOPE OF STUDY:

The report analyzes the Cancer Biopsies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices, Guidance Systems); Procedure (Tissue Biopsy, Liquid Biopsy) Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Other Cancer Types); End User (Hospitals End User, Diagnostic Laboratories End User, Ambulatory Surgical Centers End User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Agilent Technologies Inc.
• ANGLE plc
• Becton, Dickinson and Company
• Biocept Inc.
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Guardant Health Inc.
• Hologic Inc.
• Illumina Inc.
• Invitae Corporation
• Johnson & Johnson (Veridex)
• Leica Biosystems
• Menarini Silicon Biosystems
• Myriad Genetics Inc.
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Veracyte Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Cancer Biopsies - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Cancer Incidence Throws the Spotlight on Timely and Accurate Biopsy Diagnostics
  • Growing Shift Toward Precision Medicine Spurs Demand for Molecularly Guided Cancer Biopsies
  • Here's the Story: How Liquid Biopsies Are Transforming Early Detection and Monitoring of Cancer
  • Expansion of Targeted Therapies Strengthens Business Case for High-Resolution Tissue Sampling Technologies
  • Technological Innovations in Image-Guided and Minimally Invasive Biopsy Techniques Drive Market Adoption
  • Increased Use of Next-Generation Sequencing (NGS) in Oncology Generates Demand for High-Quality Biopsy Samples
  • Here's How Companion Diagnostics and Biomarker Discovery Are Shaping the Future of Cancer Biopsy Testing
  • Integration of AI and Digital Pathology Enhances Speed, Accuracy, and Scalability of Biopsy Result Interpretation
  • Growing Preference for Outpatient and Ambulatory Procedures Fuels Demand for Portable and Less-Invasive Biopsy Devices
  • Rising Emphasis on Repeat Biopsies for Treatment Monitoring Expands Opportunities in Longitudinal Cancer Care
  • Public and Private Investment in Cancer Screening Programs Drives Volume Demand for Diagnostic Biopsies
  • Increased Focus on Rare and Hard-to-Biopsy Cancers Spurs Development of Novel Sampling Methods and Devices
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cancer Biopsies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cancer Biopsies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Kits & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Software & Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Software & Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Software & Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Needle-based Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Needle-based Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Needle-based Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Vacuum-assisted Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Vacuum-assisted Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Vacuum-assisted Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Guidance Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Guidance Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Guidance Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diagnostic Laboratories End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Diagnostic Laboratories End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgical Centers End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ambulatory Surgical Centers End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ambulatory Surgical Centers End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospitals End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hospitals End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Tissue Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Tissue Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Tissue Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• JAPAN
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• CHINA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• EUROPE
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Cancer Biopsies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• FRANCE
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• GERMANY
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Cancer Biopsies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• INDIA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Cancer Biopsies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Cancer Biopsies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• AFRICA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030

IV. COMPETITION